Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on December 11, 2006, detailing two significant corporate governance changes. Firstly, the company's Compensation and Management Development Committee approved an Executive Severance Plan for certain senior executives, including Named Executive Officers (NEOs). This plan outlines severance payments and benefits for specific termination scenarios, such as involuntary termination without cause, reduction in salary, grade level, or significant job relocation. Secondly, the Board of Directors amended the company's Bylaws to implement a "majority vote" standard for the election of directors in uncontested elections. This means a director nominee must receive more "for" votes than "against" votes to be elected. If a director fails to achieve a majority in an uncontested election, they will be required to tender their resignation, which the Board will then consider. These changes reflect an effort to enhance corporate governance and executive compensation transparency.
Key Highlights
- 1Approval of a new Executive Severance Plan for senior executives and NEOs, effective December 5, 2006.
- 2Severance payments under the new plan are set at two times annual base salary for eligible executives.
- 3The plan covers benefits like continued health insurance, outplacement, and financial planning services for a specified period.
- 4Ineligible for the plan are the CEO and executives with greater severance provisions in individual agreements or local practices.
- 5Amendment to company Bylaws to require a majority vote for director elections in uncontested scenarios.
- 6A director failing to receive a majority vote in an uncontested election must tender their resignation for Board review.
- 7The Bylaw amendments aim to align with corporate governance best practices regarding director accountability.